Literature DB >> 23399616

Mechanisms of TKI-induced diarrhea in cancer patients.

Joanne M Bowen1.   

Abstract

PURPOSE OF REVIEW: Tyrosine kinase inhibitors (TKIs) are increasingly common treatments for cancer; however, their effective use is hampered by unwanted side effects. One of the most common of these is TKI-induced diarrhea, although so far very little is known about its mechanisms and the best management approaches. As such, this review will briefly cover the extent of the problem, models for researching the problem and touch on future directions for management approaches to the problem. RECENT
FINDINGS: As there is a paucity of knowledge regarding the mechanisms of TKI-induced diarrhea in humans, this review will discuss the rodent models that have been used in the investigation of TKI-induced gut injury. This will be put into context with the pharmacological targets of TKIs and how this new information might help to better tailor treatment and management of patients on these drugs.
SUMMARY: The recognition of TKI-induced diarrhea as a significant treatment side effect has prompted efforts into uncovering the pathogenesis of this complication. This will enable future patients to be better managed throughout their treatment with these highly effective cancer drugs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23399616     DOI: 10.1097/SPC.0b013e32835ec861

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  15 in total

1.  Advances in understanding and improving gastrointestinal symptoms during supportive and palliative care: a decade of progress.

Authors:  Matthew A Ciorba
Journal:  Curr Opin Support Palliat Care       Date:  2016-06       Impact factor: 2.302

2.  Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

Authors:  Anne S Tsao; James Moon; Ignacio I Wistuba; Nicholas J Vogelzang; Gregory P Kalemkerian; Mary W Redman; David R Gandara; Karen Kelly
Journal:  J Thorac Oncol       Date:  2017-06-06       Impact factor: 15.609

Review 3.  Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.

Authors:  Jun-Cheng Xuhong; Xiao-Wei Qi; Yi Zhang; Jun Jiang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

Review 4.  Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review.

Authors:  Raja Nur Firzanah Syaza Raja Sharin; Jesmine Khan; Mohamad Johari Ibahim; Mudiana Muhamad; Joanne Bowen; Wan Nor I'zzah Wan Mohamad Zain
Journal:  Biomed Res Int       Date:  2022-06-28       Impact factor: 3.246

Review 5.  Update on Immune Checkpoint Inhibitor Enterocolitis.

Authors:  Molly R Kelly-Goss; Yousef R Badran; Michael Dougan
Journal:  Curr Gastroenterol Rep       Date:  2022-10-20

6.  Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  V Hirsh; N Blais; R Burkes; S Verma; K Croitoru
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

7.  Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Tamera Corte; Francesco Bonella; Bruno Crestani; Maurits G Demedts; Luca Richeldi; Carl Coeck; Katy Pelling; Manuel Quaresma; Joseph A Lasky
Journal:  Respir Res       Date:  2015-09-24

Review 8.  Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma.

Authors:  Benjamin S Gerendash; Patricia A Creel
Journal:  Onco Targets Ther       Date:  2017-10-19       Impact factor: 4.147

9.  Rifaximin for Pertuzumab-Related GI Toxicities.

Authors:  Aixa E Soyano; Gina Reynolds; Alvaro Moreno-Aspitia; Saranya Chumsri
Journal:  Front Oncol       Date:  2017-08-08       Impact factor: 6.244

Review 10.  Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management.

Authors:  Gabriel Tao; Pavan Kumar Chityala
Journal:  Toxicol Res (Camb)       Date:  2021-05-03       Impact factor: 3.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.